The Use of Transgenic Animals to Study Drug Metabolism

Handbook of Drug Metabolism, Second Edition

Volumn , Issue , 2008, Pages 637-658

  Henderson, Colin J ^a   Wolf, C Roland ^a   Scheer, Nico ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b TaconicArtemis GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79954581429     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420076486-28     Document Type: Chapter

References (106)

1. Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, von Melchner H, Witkowski J, Woychik RP, Wurst W, Yancopoulos GD, Young SG, Zambrowicz B. The knockout mouse project. Nat Genet 2004; 36(9):921-924.
2. Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet 2001; 2(10):743-755.
3. Baer A, Bode J. Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes. Curr Opin Biotechnol 2001; 12(5):473-480.
4. Wong ET, Kolman JL, Li YC, Mesner LD, Hillen W, Berens C, Wahl GM. Reproducible doxycycline-inducible transgene expression at specific loci generated by Cre-recombinase mediated cassette exchange. Nucleic Acids Res 2005; 33(17):e147.
5. Nelson DR. Cytochrome P450 nomenclature, 2004. Methods Mol Biol 2006; 320:1-10.
6. Bernhardt R. Cytochromes P450 as versatile biocatalysts. J Biotechnol 2006; 124(1):128-145.
7. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360 (9340):1155-1162.
8. Fernandez-Salguero PM, Gonzalez FJ. Targeted disruption of specific cytochromes P450 and xenobiotic receptor genes. Methods Enzymol 1996; 272:412-430.
9. Gonzalez FJ, Kimura S. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice. Mutat Res 2001; 477(1-2):79-87.
10. Henderson CJ, Otto DM, McLaren AW, Carrie D, Wolf CR. Knockout mice in xenobiotic metabolism. Drug Metab Rev 2003; 35(4):385-392.
11. Henderson CJ, Wolf CR. Transgenic analysis of human drug-metabolizing enzymes:preclinical drug development and toxicology. Mol Interv 2003; 3(6):331-343.
12. Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, Gonzalez FJ. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci U S A 1995; 92(11):5134-5138.
13. Liang HC, McKinnon RA, Nebert DW. Sensitivity of CYP1A1 mRNA inducibility by dioxin is the same in Cyp1a2(þ/þ) wild-type and Cyp1a2(_/_) null mutant mice. Biochem Pharmacol 1997; 54(10):1127-1131.
14. Diliberto JJ, Burgin D, Birnbaum LS. Role of CYP1A2 in hepatic sequestration of dioxin:studies using CYP1A2 knock-out mice. Biochem Biophys Res Commun 1997; 236(2):431-433.
15. Tonge RP, Kelly EJ, Bruschi SA, Kalhorn T, Eaton DL, Nebert DW, Nelson SD. Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigations using Cyp1a2 null mice. Toxicol Appl Pharmacol 1998; 153(1):102-108.
16. Sinclair PR, Gorman N, Dalton T, Walton HS, Bement WJ, Sinclair JF, Smith AG, Nebert DW. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(_/_) null mutant mice. Biochem J 1998; 330(pt 1):149-153.
17. Sinclair PR, Gorman N, Walton HS, Bement WJ, Dalton TP, Sinclair JF, Smith AG, Nebert DW. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 2000; 162(1):60-67.
18. Zaccaro C, Sweitzer S, Pipino S, Gorman N, Sinclair PR, Sinclair JF, Nebert DW, De Matteis F. Role of cytochrome P450 1A2 in bilirubin degradation studies in Cyp1a2 (_/_) mutant mice. Biochem Pharmacol 2001; 61(7):843-849.
19. Dalton TP, Dieter MZ, Matlib RS, Childs NL, Shertzer HG, Genter MB, Nebert DW. Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 2000; 267(1):184-189.
20. Uno S, Dalton TP, Shertzer HG, Genter MB, Warshawsky D, Talaska G, Nebert DW. Benzo [a]pyrene-induced toxicity: paradoxical protection in Cyp1a1(_/_) knockout mice having increased hepatic BaP-DNA adduct levels. Biochem Biophys Res Commun 2001; 289(5):1049-1056.
21. Uno S, Dalton TP, Sinclair PR, Gorman N, Wang B, Smith AG, Miller ML, Shertzer HG, Nebert DW. Cyp1a1(_/_) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 2004; 196(3):410-421.
22. Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gonzalez FJ, Nebert DW. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 2006; 69(4):1103-1114.
23. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev 2006; 6(12):947-960.
24. Dragin N, Shi Z, Madan R, Karp CL, Sartor MA, Chen C, Gonzalez FJ, Nebert D. Phenotype of the Cyp1a1/1a2/1b1(_/_) triple-knockout mouse. Mol Pharmacol 2008; 73(6):1844-1856. [Epub 2008, Mar 27].
25. Dragin N, Uno S, Wang B, Dalton TP, Nebert DW. Generation of ‘humanized’ hCYP1A1_1A2_Cyp1a1/1a2(_/_) mouse line. Biochem Biophys Res Commun 2007; 359(3):635-642.
26. Pottenger LH, Jefcoate CR. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis 1990; 11(2):321-327.
27. Savas U, Bhattacharyya KK, Christou M, Alexander DL, Jefcoate CR. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression. J Biol Chem 1994; 269(21):14905-14911.
28. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet 1997; 6(4):641-647.
29. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57(14):3026-3031.
30. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, Gonzalez FJ. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12- dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A 1999; 96(5):1977-1982.
31. Gao J, Lauer FT, Dunaway S, Burchiel SW. Cytochrome P450 1B1 is required for 7, 12- dimethylbenz(a)-anthracene (DMBA) induced spleen cell immunotoxicity. Toxicol Sci 2005; 86(1):68-74.
32. Buters JT, Mahadevan B, Quintanilla-Martinez L, Gonzalez FJ, Greim H, Baird WM, Luch A. Cytochrome P450 1B1 determines susceptibility to dibenzo[a, l]pyrene-induced tumor formation. Chem Res Toxicol 2002; 15(9):1127-1135.
33. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004; 95(1):1-6.
34. Cederbaum AI. CYP2E1-biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med 2006; 73(4):657-672.
35. Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 2007; 35(1):1-8.
36. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271(20):12063-12067.
37. Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD, Gonzalez FJ. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 1998; 152(1):193-199.
38. Wong FW, Chan WY, Lee SS. Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol 1998; 153:109-118.
39. Constan AA, Sprankle CS, Peters JM, Kedderis GL, Everitt JI, Wong BA, Gonzalez FL, Butterworth BE. Metabolism of chloroform by cytochrome P450 2E1 is required for induction of toxicity in the liver, kidney, and nose of male mice. Toxicol Appl Pharmacol 1999; 160(2):120-126.
40. Ding X, Dahl A. Olfactory mucosa:composition, enzymatic localisation and metabolism. In:Doty R, ed. Handbook of Olfaction and Gustation. New York: Marcel Dekker, 2003:51-73.
41. Zhuo X, Schwob JE, Swiatek PJ, Ding X. Mouse cyp2g1 gene: promoter structure and tissuespecific expression of a cyp2g1-lacz fusion gene in transgenic mice. Arch Biochem Biophys 2001; 391(1):127-136.
42. Sheng J, Guo J, Hua Z, Caggana M, Ding X. Characterization of human CYP2G genes:widespread loss-of-function mutations and genetic polymorphism. Pharmacogenetics 2000; 10(8):667-678.
43. Zhuo X, Gu J, Behr MJ, Swiatek PJ, Cui H, Zhang QY, Xie Y, Collins DN, Ding X. Targeted disruption of the olfactory mucosa-specific Cyp2g1 gene: impact on acetaminophen toxicity in the lateral nasal gland, and tissue-selective effects on Cyp2a5 expression. J Pharmacol Exp Ther 2004; 308(2):719-728.
44. Toledo F, Liu CW, Lee CJ, Wahl GM. RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res 2006; 34(13):e92.
45. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278(15):13480-13486.
46. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, Yang W, Zhang L, Ding X. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003; 278(28):25895-25901.
47. Henderson CJ, Pass GJ, Wolf CR. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol Lett 2006; 162(1):111-117.
48. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, Wolf CR. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide:studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res 2005; 65(10):4211-4217.
49. Finn RD, McLaren AW, Carrie D, Henderson CJ, Wolf CR. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the p450 system. J Pharmacol Exp Ther 2007; 322(1):40-47.
50. Wu L, Gu J, Weng Y, Kluetzman K, Swiatek P, Behr M, Zhang QY, Zhuo X, Xie Q, Ding X. Conditional knockout of the mouse NADPH-cytochrome P450 reductase gene. Genesis 2003; 36(4):177-181.
51. Wu L, Gu J, Cui H, Zhang QY, Behr M, Fang C, Weng Y, Kluetzman K, Swiatek PJ, Yang W, Kaminsky L, Ding X. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 2005; 312(1):35-43.
52. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005; 45:51-88.
53. Mannervik B, Board PG, Hayes JD, Listowsky I, Pearson WR. Nomenclature for mammalian soluble glutathione transferases. Methods Enzymol 2005; 401:1-8.
54. Engle MR, Singh SP, Czernik PJ, Gaddy D, Montague DC, Ceci JD, Yang Y, Awasthi S, Awasthi YC, Zimniak P. Physiological role of mGSTA4-4, a glutathione S-transferase metabolizing 4-hydroxynonenal: generation and analysis of mGsta4 null mouse. Toxicol Appl Pharmacol 2004; 194(3):296-308.
55. Singh SP, Janecki AJ, Srivastava SK, Awasthi S, Awasthi YC, Xia SJ, Zimniak P. Membrane association of glutathione S-transferase mGSTA4-4, an enzyme that metabolizes lipid peroxidation products. J Biol Chem 2002; 277(6):4232-4239.
56. Dwivedi S, Sharma R, Sharma A, Zimniak P, Ceci JD, Awasthi YC, Boor PJ. The course of CCl4 induced hepatotoxicity is altered in mGSTA4-4 null (_/_) mice. Toxicology 2006; 218(1):58-66.
57. Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ, Wolf CR. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci U S A 1998; 95(9):5275-5280.
58. Black SM, Beggs JD, Hayes JD, Bartoszek A, Muramatsu M, Sakai M, Wolf CR. Expression of human glutathione S-transferases in Saccharomyces cerevisiae confers resistance to the anticancer drugs adriamycin and chlorambucil. Biochem J 1990; 268(2):309-315.
59. Black SM, Wolf CR. The role of glutathione-dependent enzymes in drug resistance. Pharmacol Ther 1991; 51(1):139-154.
60. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22(47):7369-7375.
61. Tew KD. Redox in redux: emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol 2007; 73(9):1257-1269.
62. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30(6):445-600.
63. Hayes PC, Harrison DJ, Bouchier IA, McLellan LI, Hayes JD. Cytosolic and microsomal glutathione S-transferase isoenzymes in normal human liver and intestinal epithelium. Gut 1989; 30(6):854-859.
64. Bammler TK, Smith CA, Wolf CR. Isolation and characterization of two mouse Pi-class glutathione S-transferase genes. Biochem J 1994; 298(pt 2):385-390.
65. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18(4):641-644.
66. Ritchie KJ, Henderson CJ, Wang XJ, Vassieva O, Carrie D, Farmer PB, Gaskell M, Park K, Wolf CR. Glutathione transferase pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane. Cancer Res 2007; 67(19):9248-9257.
67. Coles B, Wilson I, Wardman P, Hinson JA, Nelson SD, Ketterer B. The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. Arch Biochem Biophys 1988; 264(1):253-260.
68. Henderson CJ, Wolf CR, Kitteringham N, Powell H, Otto D, Park BK. Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A 2000; 97(23):12741-12745.
69. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ, Ronai Z. Regulation of JNK signaling by GSTp. EMBO J 1999; 18(5):1321-1334.
70. Elsby R, Kitteringham NR, Goldring CE, Lovatt CA, Chamberlain M, Henderson CJ, Wolf CR, Park BK. Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J Biol Chem 2003; 278(25):22243-22249.
71. Ishisaki A, Hayashi H, Suzuki S, Ozawa K, Mizukoshi E, Miyakawa K, Suzuki M, Imamura T. Glutathione S-transferase Pi is a dopamine-inducible suppressor of dopamine-induced apoptosis in PC12 cells. J Neurochem 2001; 77(5):1362-1371.
72. Bernardini S, Bellincampi L, Ballerini S, Ranalli M, Pastore A, Cortese C, Federici G. Role of GST P1-1 in mediating the effect of etoposide on human neuroblastoma cell line Sh-Sy5y. J Cell Biochem 2002; 86(2):340-347.
73. Bernardini S, Bernassola F, Cortese C, Ballerini S, Melino G, Motti C, Bellincampi L, Iori R, Federici G. Modulation of GST P1-1 activity by polymerization during apoptosis. J Cell Biochem 2000; 77(4):645-653.
74. Board PG, Coggan M, Chelvanayagam G, Easteal S, Jermiin LS, Schulte GK, Danley DE, Hoth LR, Griffor MC, Kamath AV, Rosner MH, Chrunyk BA, Perregaux DE, Gabel CA, Geoghegan KF, Pandit J. Identification, characterization, and crystal structure of the Omega class glutathione transferases. J Biol Chem 2000; 275(32):24798-24806.
75. Yin ZL, Dahlstrom JE, Le Couteur DG, Board PG. Immunohistochemistry of omega class glutathione S-transferase in human tissues. J Histochem Cytochem 2001; 49(8):983-987.
76. Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M, Board PG. Characterization of the omega class of glutathione transferases. Methods Enzymol 2005; 401:78-99.
77. Chowdhury UK, Zakharyan RA, Hernandez A, Avram MD, Kopplin MJ, Aposhian HV. Glutathione-S-transferase-omega [MMA(V) reductase] knockout mice: enzyme and arsenic species concentrations in tissues after arsenate administration. Toxicol Appl Pharmacol 2006; 216(3):446-457.
78. Urade Y, Eguchi N, Aritake K, Hayaishi O. [Functional analyses of lipocalin-type and hematopoietic prostaglandin D synthases]. Nippon Yakurigaku Zasshi 2004; 123(1):5-13.
79. Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000; 463(3):247-283.
80. Fujimoto K, Arakawa S, Watanabe T, Yasumo H, Ando Y, Takasaki W, Manabe S, Yamoto T, Oda S. Generation and functional characterization of mice with a disrupted glutathione Stransferase, theta 1 gene. Drug Metab Dispos 2007; 35(12):2196-2202.
81. Fernandez-Canon JM, Baetscher MW, Finegold M, Burlingame T, Gibson KM, Grompe M. Maleylacetoacetate isomerase (MAAI/GSTZ)-deficient mice reveal a glutathione-dependent nonenzymatic bypass in tyrosine catabolism. Mol Cell Biol 2002; 22(13):4943-4951.
82. Lim CE, Matthaei KI, Blackburn AC, Davis RP, Dahlstrom JE, Koina ME, Anders MW, Board PG. Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol 2004; 165(2):679-693.
83. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006; 58(4):685-704.
84. Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 2006; 38(3):515-597.
85. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 2001; 98(6):3369-3374.
86. Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 2001; 29(11):1467-1472.
87. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000; 407(6806):920-923.
88. Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004; 279(47):49517-49522.
89. Wei P, Zhang J, Dowhan DH, Han Y, Moore DD. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2002; 2(2):117-126.
90. Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C. Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 2003; 64(1):42-50.
91. Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J Biol Chem 2004; 279(12):11336-11343.
92. Campbell SJ, Carlotti F, Hall PA, Clark AJ, Wolf CR. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 1996; 109(11):2619-2625.
93. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ, Winton DJ. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 2004; 126(5):1236-1246.
94. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, Evans RM. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000; 406(6794):435-439.
95. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002; 298(5592):422-424.
96. Xie W, Evans RM. Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 2001; 276(41):37739-37742.
97. Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 2007; 35(2):194-200.
98. Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 2004; 64(11):3849-3854.
99. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ. The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 2008; 101(1):132-139.
100. Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 2006; 46:41-64.
101. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, Gonzalez FJ. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001; 60(6):1260-1267.
102. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ. Expression of the human CYP3A4 gene in the small intestine of transgenic mice:in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 2003; 31(5):548-558.
103. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117(11):3583-3592.
104. Chen S, Beaton D, Nguyen N, Senekeo-Effenberger K, Brace-Sinnokrak E, Argikar U, Remmel RP, Trottier J, Barbier O, Ritter JK, Tukey RH. Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 2005; 280(45):37547-37557.
105. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard, JA, Yuspa, SH, Coffey, RJ, Magnuson, T. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269(5221):230-234.
106. Ridgway WM, Healy B, Smink LJ, Rainbow D, Wicker LS. New tools for defining the ‘genetic background’ of inbred mouse strains. Nat Immunol 2007; 8(7):669-673.